Tau-Targeting Therapies May Transform Alzheimer's Treatment Despite Clinical Uncertainties

Key Takeaways

• Voyager Therapeutics' innovative focus on tau-targeting programs in Alzheimer's could capture significant market demand, boosting future earnings and revenue.
  
• Strategic partnerships and promising technological advancements ensure non-dilutive revenue growth and potential stock revaluation, enhancing long-term net margins and earnings per share.
  
• Reliance on external partnerships and uncertainties in gene therapy development present financial risks that could impact Voyager's future revenues and market positioning.

Catalysts

A biotechnology company, focuses on the human genetics for the cure of neurological diseases.

• Voyager Therapeutics' pipeline includes 4 wholly-owned and 13 partnered programs, with multiple upcoming opportunities to generate clinical data, which could significantly impact future revenue growth if successful.
  
• The company's emphasis on targeting tau in Alzheimer's disease with their tau silencing and anti-tau antibody programs positions them to capitalize on the high unmet need and potential market, potentially boosting future earnings and revenue.
  
• Voyager's TRACER capsid platform for IV-delivered CNS-directed gene therapies, coupled with their ALPL-based nonviral shuttle, could provide them with a technological edge, improving long-term net margins through efficient delivery methods.
  
• Current partnerships contribute to non-dilutive revenue, and with $8.2 billion in potential future milestone payments, securing additional partnerships could significantly enhance Voyager's future earnings.
  
• The advancement of the VY1706 tau silencing program into IND-enabling studies and its progress toward IND in 2026, alongside promising data in anti-tau antibodies, may drive a positive revaluation of their stock, potentially enhancing EPS growth.

Voyager Therapeutics Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Voyager Therapeutics's revenue will decrease by 3.0% annually over the next 3 years.
• Analysts are not forecasting that Voyager Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Voyager Therapeutics's profit margin will increase from -81.3% to the average US Biotechs industry of 19.3% in 3 years.
• If Voyager Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $14.1 million (and earnings per share of $0.25) by about April 2028, up from $-65.0 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 79.3x on those 2028 earnings, up from -2.4x today. This future PE is greater than the current PE for the US Biotechs industry at 19.3x.
• Analysts expect the number of shares outstanding to grow by 1.5% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.76%, as per the Simply Wall St company report.

Voyager Therapeutics Future Earnings Per Share Growth

Risks

• The company faces uncertainties in its clinical pipeline, such as the SOD1 silencing gene therapy program moving back into the research stage due to not meeting target profiles, which could delay product development and impact future revenue and earnings.
  
• The gene therapy field has seen continued setbacks, and despite potential, there is significant risk associated with proving clinical benefit and commercial success, which could hinder Voyager's market share growth and revenue potential.
  
• Significant reliance on external partnerships for funding and milestone payments introduces financial risk; changes in partnerships could disrupt cash flow, impacting net margins.
  
• The success of the tau-targeting therapies relies on evolving third-party data and external scientific breakthroughs, which introduces uncertainty in the validation and commercial viability of Voyager's products, potentially impacting long-term earnings.
  
• The field of CNS-targeted therapies, particularly gene therapies, is highly competitive; any lag in Voyager's ability to demonstrate superiority or sustained clinical benefit over competitors could negatively impact future revenues and market positioning.

Valuation

• The analysts have a consensus price target of $16.1 for Voyager Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $9.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $73.0 million, earnings will come to $14.1 million, and it would be trading on a PE ratio of 79.3x, assuming you use a discount rate of 6.8%.
• Given the current share price of $2.85, the analyst price target of $16.1 is 82.3% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.